BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 12697938)

  • 21. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    Lachaine J; Mathurin K; Barakat S; Couban S
    Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acute promyelocytic leukemia: state-of-the-art management].
    Asou N
    Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
    Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
    Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the treatment of relapsed acute promyelocytic leukemia.
    Douer D
    Acta Haematol; 2002; 107(1):1-17. PubMed ID: 11818666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
    Ma Y; Liu L; Jin J; Lou Y
    PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute promyelocytic leukemia: evolving therapeutic strategies.
    Tallman MS; Nabhan C; Feusner JH; Rowe JM
    Blood; 2002 Feb; 99(3):759-67. PubMed ID: 11806975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
    Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
    Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
    Sasaki K; Ravandi F; Kadia T; DiNardo CD; Yilmaz M; Short N; Jabbour E; Patel KP; Loghavi S; Pierce S; Borthakur G; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):375-381. PubMed ID: 38431521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of acute promyelocytic leukemia.
    Tallman MS; Nabhan C
    Curr Oncol Rep; 2002 Sep; 4(5):381-9. PubMed ID: 12162911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
    Li J; Zhu H; Hu J; Mi J; Chen S; Chen Z; Wang Z
    Int J Hematol; 2014 Jul; 100(1):38-50. PubMed ID: 24938378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modern approaches to treating acute promyelocytic leukemia.
    Sanz MA; Lo-Coco F
    J Clin Oncol; 2011 Feb; 29(5):495-503. PubMed ID: 21220600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current treatment strategy of acute promyelocytic leukemia.
    Mi J
    Front Med; 2011 Dec; 5(4):341-7. PubMed ID: 22198746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
    Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
    Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
    Fujita H; Asou N; Iwanaga M; Hyo R; Nomura S; Kiyoi H; Okada M; Inaguma Y; Matsuda M; Yamauchi T; Ohtake S; Izumi T; Nakaseko C; Ishigatsubo Y; Shinagawa K; Takeshita A; Miyazaki Y; Ohnishi K; Miyawaki S; Naoe T;
    Cancer Sci; 2013 Oct; 104(10):1339-45. PubMed ID: 23837667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.
    Yanada M; Tsuzuki M; Fujita H; Fujimaki K; Fujisawa S; Sunami K; Taniwaki M; Ohwada A; Tsuboi K; Maeda A; Takeshita A; Ohtake S; Miyazaki Y; Atsuta Y; Kobayashi Y; Naoe T; Emi N;
    Blood; 2013 Apr; 121(16):3095-102. PubMed ID: 23412094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
    Breccia M; Lo-Coco F
    Expert Opin Pharmacother; 2012 May; 13(7):1031-43. PubMed ID: 22468778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the standard regimen for patients with acute promyelocytic leukemia?
    Lo-Coco F; Cicconi L
    Curr Hematol Malig Rep; 2014 Jun; 9(2):138-43. PubMed ID: 24729066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
    Mayorga J; Richardson-Hardin C; Dicke KA
    Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
    J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.